Genzyme Renal Division President John Butler: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Butler speaks with the DAILY about the Renvela launch, plans for a next-generation phosphate binder and other candidates in the biotech’s renal pipeline.
You may also be interested in...
Keryx Suffers Setback As Diabetic Nephropathy Candidate Fails Phase III Study
Firm falls back on mid-stage pipeline candidates in chronic kidney disease, kidney cancer.
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.
Advisory Committee Rejects Surrogate Endpoint For Phosphate Binders
Sponsors are seeking to expand the indication of the CKD therapies without clinical data.